Delayed vs Immediate Umbilical Cord Clamping in Preterm Birth

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares delayed cord clamping to immediate clamping in preterm infants born between 32 and 37 weeks gestation at a Tunisian maternity center. Participants are randomized to follow a predefined protocol for cord clamping timing, and early neonatal outcomes such as respiratory status, resuscitation needs, hemoglobin levels, and early morbidity and mortality are collected. The setting is a tertiary maternity center in Tunisia, with parental consent obtained per local ethics requirements. The study aims to determine if delayed clamping improves placental transfusion and early adaptation without introducing undue risk.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Preterm neonates born at gestational age between 32 and 37 weeks
* Live-born infants delivered in the study center
* Singleton pregnancies
* Parental consent obtained when applicable according to institutional ethical requirements

Exclusion Criteria:

* Major congenital malformations or chromosomal abnormalities
* Need for immediate advanced resuscitation at birth
* Severe fetal distress requiring emergency obstetric intervention incompatible with protocol allocation
* Placental conditions contraindicating delayed cord clamping (e.g., placental abruption with maternal instability, placenta previa bleeding, Placenta accreta spectrum)
* Intra Uterin Growth Restriction with abnormal umbilical artery Doppler velocimetry

Where it's running

• Maternity and neonatology center of Tunis
  Tunis, Tunis Governorate, Tunisia Recruiting

Study contacts

• Study coordinator: Mohammed Amine MA Hannachi, Assistant professor
• Email: mohammedamine.hannachi@fmt.utm.tn
• Phone: +21699696332

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DISC-0974-201 for adults with IBD-related anemia

  This Phase 2 trial will test whether DISC-0974-201 helps adults with inflammatory bowel disease who have anemia driven by inflammation.

  Recruiting at 15 sites Phase 2 Disc Medicine, Inc · Birmingham, Alabama and 14 other locations · NCT07368972

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Iron status at ICU discharge in adults with anemia after critical illness

  We are testing whether iron deficiency is common at ICU discharge and whether it relates to how well patients recover after leaving the ICU.

  Recruiting Università degli Studi di Ferrara · Brussels and 3 other locations · NCT07781540

• Luspatercept for anemia due to chronic kidney disease

  This study tests whether luspatercept can raise hemoglobin levels in people with anemia caused by CKD and whether it is safe.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07725497

• Elritercept vs. placebo for adults with myelofibrosis and anemia on ruxolitinib

  This study tests whether elritercept can improve anemia in adults with myelofibrosis who are taking ruxolitinib, compared with placebo.

  Recruiting at 11 sites Phase 3 Takeda · Gilbert, Arizona and 213 other locations · NCT07623161

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.